- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04209348
The Project Wellness Pilot Feasibility Randomized Controlled Trial
Project Wellness: A Pilot Feasibility Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- The University of Tennessee Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-40 years
- Singleton viable pregnancy with low suspicion for clinically significant abnormality or aneuploidy
- Hyperglycemia after 24 weeks identified by:
One step diagnostic procedure 75-g Oral Glucose Tolerance Test (OGTT) after an overnight fast, with plasma glucose measured fasting and at 1 and 2 hrs, and any of the following plasma glucose values are met or exceeded: Fasting: 92 mg/dL (5.1 mmol/L)
- hr: 180 mg/dL (10.0 mmol/L)
- hr: 153 mg/dL (8.5 mmol/L)
For the Two step diagnostic procedure, only Step 1 (i.e., at risk for GDM) is required for eligibility:
Step 1: 50-g glucose screening test (non-fasting), with plasma glucose measured at 1-hr ≥130 mg/dL
Any other abnormal value on oral glucose tolerance testing associated with macrosomia
- English speaker and comfortable completing surveys in English (i.e., no translator needed)
- Planning to remain in the area for baby's first year
Exclusion Criteria:
- Previously diagnosed with diabetes (i.e., Type I or Type II diabetes) outside of pregnancy
- Contraindications to exercise (i.e., absolute contraindications according to published recommendations for exercise during pregnancy), as follows:
Hemodynamically significant heart disease, Restrictive lung disease, Incompetent cervix/cerclage, Persistent second or third trimester bleeding, Placenta previa or vasa previa after 26 weeks gestation, Premature labor during the current pregnancy, Ruptured membranes, Preeclampsia/pregnancy-induced hypertension, severe anemia
- Currently non-smoker
- Current illicit drug use
- Current use of daily medications known to alter insulin resistance and metabolic profiles (e.g., metformin, corticosteroids, anti-psychotics)
- Currently taking medication for polycystic ovarian syndrome (PCOS) (i.e., history of PCOS okay as long as she is not currently taking medication for PCOS)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Physical Activity Intervention
The behavioral physical activity (PA) intervention focuses on walking, or stepping in place when it is not possible to walk (e.g., stormy weather).
The primary goal of the PA intervention is to achieve at least 30 minutes per day of walking/stepping in place.
The secondary goal is to use a PA tracker (e.g., the Fitbit Charge 3 provided by the intervention) to log and review walking/stepping, and to accumulate at least 3,000 steps during their 30 minutes of walking/stepping each day.
|
Motivational interviewing techniques helped participants set reasonable, specific, and achievable individual goals at each session: a duration (i.e., minutes) and frequency (i.e., days of the week) of walking or stepping, and potentially, a step count (i.e., a proxy for intensity).
Individual goals often differed from the program goal in an effort to meet the participants 'where they are'.
Other Names:
|
Active Comparator: Wellness Education
The Wellness Education intervention will deliver information on mom and baby wellness that is unrelated to physical activity, diet, metabolism, or weight (e.g., immunizations during pregnancy and encouragement to immunize the baby on schedule, postpartum contraceptive options and developing a contraceptive plan, infant car seats & safety checks).
|
The following topics were addressed: postpartum contraception, maternal immunizations, infant immunizations, car seat safety and planning for your hospital stay, and safe sleep and skin to skin.
No information on PA was provided to the control group (i.e., neither encouragement for PA nor instructions to limit PA).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Self-reported Physical Activity (Assessed by Pregnancy Physical Activity Questionnaire) From Baseline to Follow-up
Time Frame: approximately 6 weeks
|
Change in self-reported moderate to vigorous intensity walking or running activity within the sports & exercise domain, as assessed by Pregnancy Physical Activity Questionnaire (i.e., measure at follow-up study visit minus the measure at baseline study visit). Reference: Chasan-Taber L, Schmidt MD, Roberts DE, Hosmer D, Markenson G, Freedson PS. Development and Validation of a Pregnancy Physical Activity Questionnaire. Med Sci Sports Exerc. 2004;36(10):1750-1760. |
approximately 6 weeks
|
Change in Physical Activity Assessed by ActiGraph Monitoring Device From Baseline to Follow-up
Time Frame: approximately 6 weeks
|
Change in minutes per day of walk/run activity, as assessed by ActiGraph monitoring device (i.e., measure at follow-up study visit minus the measure at baseline study visit). Reference: Hibbing PR, Lamunion SR, Kaplan AS, Crouter SE. Estimating Energy Expenditure with ActiGraph GT9X Inertial Measurement Unit. Med Sci Sports Exerc. May 2018;50(5):1093-1102. |
approximately 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neonatal Subscapular Skinfolds
Time Frame: Within 5 days of birth
|
Neonatal Subscapular Skinfolds (i.e., caliper measurement to assess neonatal body composition)
|
Within 5 days of birth
|
Birthweight-for-gestational-age Z-score
Time Frame: Within 5 days of birth
|
Birthweight-for-gestational-age Z-score based on the sex- and gestational-age-specific birth-weight distributions of the 2017 U.S. Natality files. Z-scores more extreme than -1.645 and +1.645 indicate birthweight-for-gestational-age-and-sex at <10th and >90th percentiles, respectively, and thus indicate increased risks for adverse health outcomes (as the relationship is U-shaped). A Z-score of 0 represents birthweight-for-gestational-age-and-sex at the 50th percentile. Reference: Aris IM, Kleinman KP, Belfort MB, Kaimal A, Oken E. A 2017 U.S. Reference for Singleton Birth Weight Percentiles Using Obstetric Estimates of Gestation. Pediatrics. Jul 2019;144(1). |
Within 5 days of birth
|
Collaborators and Investigators
Investigators
- Principal Investigator: Samantha F Ehrlich, PhD, Assistant Professor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UTGSM-04547
- K01DK105106 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes, Gestational
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
University of Texas Southwestern Medical CenterCompletedMild Gestational DiabetesUnited States
-
Royal College of Surgeons, IrelandHealth Research Board, IrelandUnknownPre-Gestational Diabetes
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Intermountain Health Care, Inc.Withdrawn
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Baylor College of MedicineRecruitingGestational Diabetes MellitusUnited States
-
Joslin Diabetes CenterRoche DiagnosticsCompletedGestational Diabetes MellitusUnited States
-
Ludwig-Maximilians - University of MunichGerman Federal Ministry of Education and Research; Helmholtz Zentrum MünchenCompletedGestational Diabetes MellitusGermany
Clinical Trials on Physical Activity Intervention
-
Brown UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
University of ConnecticutNational Institutes of Health (NIH); National Center for Complementary and...RecruitingChronic Low Back PainUnited States
-
Institut Català d'OncologiaUnknownRecurrence | Breast NeoplasmsSpain
-
Centre Leon BerardNational Cancer Institute, FranceNot yet recruitingMetastatic Testicular CancerFrance
-
University of California, DavisActive, not recruitingBehavior, HealthUnited States
-
Jamie JacksonNational Heart, Lung, and Blood Institute (NHLBI)CompletedPhysical Activity | Cardiovascular Disease OtherUnited States
-
Brown UniversityNational Cancer Institute (NCI)Not yet recruiting
-
Jamie JacksonCompletedPhysical Activity | Cardiovascular Disease OtherUnited States
-
The Miriam HospitalUnknownStroke | Sedentary Lifestyle | Ischemic Attack, Transient | ExerciseUnited States
-
Tel-Aviv Sourasky Medical CenterUnknownObesity | Overweight | Learning DisabilityIsrael